QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Novavax, Inc. (NVAX)

Healthcare

No action
Fundamental
2
Sentiment
2
Technical
1

Do Nothing: fundamentalScore 2 and qualitativeScore 2 are both below the required floor of 3, so no bullish entry may be admitted (the SHADOW_FST9 branch is ineligible because the shadow flag rendered false); the chart is bearish in any case, with price below every moving average and MACD expanding negative.

Analysis as of 2026-11-15· more than 2 trading days ago

Company overview

Novavax, Inc. is a biotechnology company focused on developing vaccines for serious infectious diseases. Its pipeline includes NVX-CoV2373, a COVID-19 vaccine candidate, NanoFlu, a seasonal influenza vaccine, and ResVax, an RSV vaccine. The company collaborates with Takeda Pharmaceutical for its COVID-19 vaccine.

Fundamental

weak
Fundamental2
Weak fundamentals

Novavax's fundamentals are weak, with negative cash flow, a distressed Z-score, and reliance on one-time revenues.

Novavax's FY2025 GAAP profit was manufactured by one-time Canadian and New Zealand contract-termination revenue and Sanofi milestones, not by the operating business: on a trailing basis revenue is $411.6M with an -18.6% net margin, roughly -$246M of free cash flow and negative stockholders' equity. Liquidity is the counterweight — $627M of cash and securities against $295M of debt, no maturity wall, a positive going-concern conclusion and covenant compliance — and operating losses are narrowing sharply after deep cost cuts. Both discounted-cash-flow models are negative, the Altman Z-Score sits in distress territory, the consensus price target is below the market price and no insider is buying. Weak, cash-consuming and dependent on partner milestones: a watchlist name rather than an actionable one.

Sentiment

weak
Sentiment2
Mixed sentiment

Sentiment is mixed, with no clear catalyst and a lack of retail engagement.

The dominant in-window catalyst is the 2026-11-05 Q3 2026 print (announced), which reads neutral on market reception — a $68.3M revenue beat and a $145M raise to FY26 adjusted revenue guidance offset by a $31.4M net loss, a profitability target pushed to 2029 and a trimmed sell-side target. The media delta is determinate and mildly negative (baseline polarity ≈ +0.17 over 19 scored items → scoring ≈ +0.05 over 6), i.e. coverage cooled to effectively neutral; the Red-Flag Screen surfaced no severe flag but the moderate conflicting-catalyst-signals cap applies (ceiling 3), and the setup's own weakness — a lone trailing neutral print, no forward-dated driver and retail indeterminate on a 403 block — resolves it below that ceiling.

Technical

very weak
Technical1
Bearish trend

The technical outlook is bearish, with the stock trading below all major moving averages and showing negative momentum.

Price 8.525 sits below every trend reference on the board — SMA20 10.10, SMA50 10.54, SMA200 9.33, EMA9 9.68, EMA21 10.13, WMA21 9.93 and the 8.61 daily VWAP — a fully broken trend stack, and MACD (-0.37 line vs -0.20 signal, histogram -0.17 and widening from -0.11) shows downside momentum accelerating, not exhausting. ADX14 at 24.05 and rising with price beneath the entire MA stack reads as strengthening directional downtrend rather than a base. RSI14 37.67 is weak without being capitulatory, while Williams %R at -93.68 and a five-session slide from 10.89 to 8.525 (-21.7%, including -9.69% on 2026-11-12) on expanding down-day volume leave only a low-quality reflex-bounce case, not a bullish setup. Chart quality scores 1 (bearish / broken structure); the action is separately hard-blocked by fundamentalScore 2 and qualitativeScore 2.

You’re looking at 2026-11-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.